Group Chief Executive Officer & Executive Director, Banco Santander, S.A.
Most recently reported pay: €11M. No year-by-year proxy breakdown is on file — common for foreign private issuers and recently listed companies, which do not file a US proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Oct 25, 2026https://www.globenewswire.com/news-release/2026/10/25/3387719/0/en/libtayo-cemiplimab-longer-term-data-show-increasing-and-clinically-meaningful-overall-survival-benefit-with-adjuvant-treatment-in-high-risk-cutaneous-squamous-cell-carcinoma-cscc.htmlsentiment +0.80
Press Release : Availability of the aide-mémoire for Q3 2026 results
Oct 6, 2026https://www.globenewswire.com/news-release/2026/10/06/3375120/0/en/press-release-availability-of-the-aide-m%C3%A9moire-for-q3-2026-results.htmlsentiment +0.00
Big Pharma Got Its Tariff Exemption. The Biotech ETF Barely Blinked
Sep 30, 2026https://247wallst.com/investing/2026/09/30/big-pharma-got-its-tariff-exemption-the-biotech-etf-barely-blinked/sentiment +0.20
EWP: Spanish Equities Appear To Be Fairly Valued
Sep 25, 2026https://seekingalpha.com/article/4949872-ewp-spanish-equities-appear-to-be-fairly-valuedsentiment -0.10
Unaudited interim results for the three-and six-month periods ended 30 June 2026
Sep 22, 2026https://www.globenewswire.com/news-release/2026/09/22/3365948/0/en/unaudited-interim-results-for-the-three-and-six-month-periods-ended-30-june-2026.htmlsentiment +0.00
Banco Santander: A High-ROTE Behemoth Hidden In Plain Sight
Sep 14, 2026https://seekingalpha.com/article/4945914-santander-stock-high-rote-behemoth-hidden-plain-sightsentiment +0.90
